jCell: allogeneic cell therapy for retinitis pigmentosa

admin_vjr_user — Tue, 04 Jan 2022 15:29:59 +0000

Gil Carrasquinho, MD, MBA, Santen Pharmaceutical Co. Ltd., discusses the mechanism of action of jCell Therapy, an investigational allogeneic cell therapy for retinitis pigmentosa (RP), a degenerative retinal disease. Human retinal progenitor cells (RPCs) are administered via intravitreal injection causing the release neurotropic factors, resulting in a reduction in photoreceptor cell death and restoration of surviving photoreceptor and retinal ganglion cell function. A Phase IIb trial (NCT04604899) evaluating jCell in patients with RP demonstrated promising efficacy and tolerability data. This interview took place at the International Society for Stem Cell Research (ISSCR) 2021 Annual Meeting.

Advanced therapies for retinitis pigmentosa

admin_vjr_user — Tue, 04 Jan 2022 15:29:57 +0000

Gil Carrasquinho, MD, MBA, Santen Pharmaceutical Co. Ltd., provides an overview of the current research landscape in retinitis pigmentosa (RP), a degenerative retinal disease that leads to a loss of vision over time. While current treatment options for RP are limited, the gene therapy voretigene neparvovec was recently approved, however, this can only be used to treat a small subset of patients with RP. A number of cell and gene therapies are currently under investigation, however the high level of genotypic and phenotypic heterogeneity seen in patients with RP makes the design of clinical trials and therefore the development and approval of new therapies challenging. This interview took place at the International Society for Stem Cell Research (ISSCR) 2021 Annual Meeting.

Gil Carrasquinho – VJRegenMed

jCell: allogeneic cell therapy for retinitis pigmentosa

Advanced therapies for retinitis pigmentosa